Lubiprostone is a locally acting chloride channel activator, specifically a type-2 chloride channel (ClC-2) activator, used for the treatment of chronic idiopathic constipation (CIC) and irritable bowel syndrome with constipation (IBS-C). It works by increasing intestinal fluid secretion, which softens stool and promotes bowel motility without systemic effects on gut motility. It is a prostaglandin E1 derivative but lacks anti-inflammatory activity.
Adult: For CIC: 24 mcg orally twice daily with food and water. For IBS-C: 8 mcg orally twice daily with food and water. Note: The 24 mcg strength is primarily used for CIC in India.
Note: Take orally with food and a full glass of water to reduce the incidence of nausea. Swallow the soft gelatin capsule whole; do not break, crush, or chew. Can be taken with or immediately after meals. If a dose is missed, take it as soon as remembered with food. If it is almost time for the next dose, skip the missed dose and continue with the regular schedule. Do not double the dose.
Lubiprostone selectively activates type-2 chloride channels (ClC-2) on the apical membrane of intestinal epithelial cells, particularly in the duodenum and jejunum. This activation increases chloride secretion into the intestinal lumen. The chloride ions create an osmotic gradient that draws sodium and water passively into the lumen, increasing intestinal fluid secretion. This results in softening of stool, increased stool volume, and enhanced intestinal transit without stimulating peristaltic contractions directly.
Pregnancy: Pregnancy Category C (US FDA). Animal studies have shown fetal loss. There are no adequate and well-controlled studies in pregnant women. Use during pregnancy only if the potential benefit justifies the potential risk to the fetus. Avoid use unless clearly needed.
Driving: Lubiprostone may cause dizziness. Patients should be cautioned about operating machinery or driving until they are certain that lubiprostone does not affect them adversely.
| Antidiarrheal agents (e.g., Loperamide, Diphenoxylate/Atropine) | May antagonize the therapeutic effect of lubiprostone. Concomitant use is not recommended. | Major |
| Drugs that may cause nausea (e.g., Opioids, Chemotherapy) | May have additive effect, increasing the incidence and severity of nausea. | Moderate |
| Other laxatives or enemas | May increase the risk of severe diarrhea and electrolyte imbalance. Use with caution. | Moderate |
| Drugs that affect GI motility (e.g., Anticholinergics, Prokinetics) | Theoretical interaction; clinical significance unknown. Monitor for altered effects. | Minor |